Aptima HPV E6/E7 mRNA 16,18/45基因型检测技术在宫颈癌前病变和宫颈癌筛查中的应用价值

目的 探讨人乳头瘤病毒(HPV)E6/E7 mRNA 16,18/48基因型检测在宫颈癌筛查中的应用价值.方法 收集福建省宁德市闽东医院2015-2019年间Aptima HPV E6/E7 mRNA定性检测阳性患者871例,进行Aptima HPV E6/E7 mRNA 16、18/45基因型检测,追踪其宫颈液基细胞...

Clinical application of Aptima HPV E6/E7mRNA 16 and 18/45 technology in cervical cancer and precancerous lesions

Objective To explore the application value of human papillomavirus(HPV)E6/E7 mRNA 16,18/48 genotype detection in cervical cancer screening.Methods A total of 871 patients with positive Aptima HPV E6/E7 mRNA qualitative detection from 2015 to 2019 in Mindong Hospital of Ningde City,Fujian Province were collected.Aptima HPV E6/E7 mRNA 16 and 18/45 genotypes were tested and their cervical liquid-based cytology and colposcopy biopsy.With histopathological results as the"gold standard",the two detection methods TCT and Aptima HPV were compared in the risk prediction ability of cervical high-grade lesions(HSIL)and cervical cancer.Results The RR value of≥HSIL in the 16/18/45+group was 1.490 times(95%CI:1.252~1.772)of the other 11 types of HPV+and 1.332 times(95%CI:1.152~1.541)of the TCT+group,but it was low in the TCT+combined 16/18/45+group,the differences were statistically significant(P<0.05).Conclusion TCT alone has a certain missed diagnosis rate,and HPV testing needs to be combined to improve the sensitivity of diagnosis;HPV E6/E7 mRNA detection,especially 16/18/45 typing detection,has better risk prediction ability for≥HSIL than TCT detection;HPV E6/E7 mRNA combined with TCT examination has important clinical significance in reducing the missed diagnosis rate of HSIL.